Breast Cancer Coverage from Every Angle
Advertisement
Advertisement

Nancy U. Lin, MD, on the HER2CLIMB Trial: Triplet Regimen for Metastatic Breast Cancer

Posted: Friday, May 29, 2020

Nancy U. Lin, MD, of Dana-Farber Cancer Institute, talks about whether the positive results with tucatinib, trastuzumab, and capecitabine from the HER2CLIMB study of patients with previously treated HER2-positive metastatic breast cancer that had metastasized to the brain are expected to change clinical practice in the near future.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.